Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award - PA: Biomedical/Clinical HIV/AIDS Research

McGill University

$66,000.00

The contribution of cellular PRMT6 to HIV-1 pathogenesis.

FY 2009-10

Summary
Human immunodeficiency virus type 1 (HIV-1) readily replicates in human immune cells, evades the host immune response by mutating frequently, and causes disease by ultimately depleting the cells humans use to protect themselves. However, HIV-1 infection may be controlled for a number of years prior to the onset of disease and this progression towards AIDS is a result of complex host and viral determinants. The natural development of HIV-1 infection varies widely from person to person and can result in rapid disease progressors to asymptomatic long term non progressors. The reasons for this are still obscure; however, the recent discovery of host restriction factors, which function to inhibit retroviral activities, may shine light on this process. Host restriction factors PRMT6, a protein arginine methyltranferase, compromises HIV-1 protein function by methylating HIV-1 Tat, Nef and nucleocapsid (NC). However over the natural course of infection HIV-1 eventually manages to circumvent the restrictive effects of PRMT6. Our preliminary data suggest that PRMT6 is targeted by Vif for degradation and we aim to elucidate the mechanism behind this degradation. The importance of PRMT6 in HIV-1 pathogenesis was further demonstrated by a recent publication by Le Clerc et al. that establishes in a genome wide study, the association between a single nucleotide polymorphism (SNP) in the PRMT6 gene and rapid progression of the disease. We also wish to study the PRMT6 variant and its effect on HIV-1 protein methylation and its susceptibility to Vif-mediated degradation. In light of the latest intriguing findings on PRMT6 and with the expertise of Dr. Wainberg and his team, we believe that studying HIV-1 PRMT6 interaction will most certainly reveal exciting insight into the regulation of HIV-1 transcription, the innate immunity against the virus, viral latency and AIDS disease progression. Such insight will ultimately provide new drug targets and enable better disease management
Program
Doctoral Research Award - PA: Biomedical/Clinical HIV/AIDS Research
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
195918
Name
Singhroy Diane N
Region
Québec
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
The contribution of cellular PRMT6 to HIV-1 pathogenesis.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$66,000
Cihrequipment2
$0
Programname2
Doctoral Research Award - PA: Biomedical/Clinical HIV/AIDS Research
Keyworddelim
Arginine Methylation; Hiv/Aids; Host Restriction Factor; Prmt6; Proteasomal Degradation; Rapid Disease Progression; Site Directed Mutagenesis; Snp Variants; Ubiquitination Assay; Virus Propagation And Titering
Abstract
Human immunodeficiency virus type 1 (HIV-1) readily replicates in human immune cells, evades the host immune response by mutating frequently, and causes disease by ultimately depleting the cells humans use to protect themselves. However, HIV-1 infection may be controlled for a number of years prior to the onset of disease and this progression towards AIDS is a result of complex host and viral determinants. The natural development of HIV-1 infection varies widely from person to person and can result in rapid disease progressors to asymptomatic long term non progressors. The reasons for this are still obscure; however, the recent discovery of host restriction factors, which function to inhibit retroviral activities, may shine light on this process. Host restriction factors PRMT6, a protein arginine methyltranferase, compromises HIV-1 protein function by methylating HIV-1 Tat, Nef and nucleocapsid (NC). However over the natural course of infection HIV-1 eventually manages to circumvent the restrictive effects of PRMT6. Our preliminary data suggest that PRMT6 is targeted by Vif for degradation and we aim to elucidate the mechanism behind this degradation. The importance of PRMT6 in HIV-1 pathogenesis was further demonstrated by a recent publication by Le Clerc et al. that establishes in a genome wide study, the association between a single nucleotide polymorphism (SNP) in the PRMT6 gene and rapid progression of the disease. We also wish to study the PRMT6 variant and its effect on HIV-1 protein methylation and its susceptibility to Vif-mediated degradation. In light of the latest intriguing findings on PRMT6 and with the expertise of Dr. Wainberg and his team, we believe that studying HIV-1 PRMT6 interaction will most certainly reveal exciting insight into the regulation of HIV-1 transcription, the innate immunity against the virus, viral latency and AIDS disease progression. Such insight will ultimately provide new drug targets and enable better disease management
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Singhroy, Diane N
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $66,000~ $0~